Madrigal Pharmaceuticals Inc
MDGL
Company Profile
Business description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Contact
200 Barr Harbor Drive
Suite 200, Four Tower Bridge
West ConshohockenPA19428
USAT: +1 267 824-2827
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
528
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,779.00 | 6.00 | 0.07% |
CAC 40 | 7,665.91 | 25.64 | -0.33% |
DAX 40 | 23,909.61 | 123.61 | -0.51% |
Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
FTSE 100 | 8,760.96 | 37.95 | -0.43% |
HKSE | 24,072.28 | 211.87 | -0.87% |
NASDAQ | 20,369.73 | 96.27 | 0.47% |
Nikkei 225 | 40,019.94 | 467.45 | -1.15% |
NZX 50 Index | 12,646.56 | 43.74 | 0.35% |
S&P 500 | 6,204.95 | 31.88 | 0.52% |
S&P/ASX 200 | 8,548.50 | 6.20 | 0.07% |
SSE Composite Index | 3,444.43 | 20.20 | 0.59% |